Third Rock Ventures V, L.P.
SEC CIK 1778071 · EDGAR
BoughtSold
Most active insiders at SEPN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | — | $63.45M |
| 2 | Shaikhly Samira | CHRO | — | $2.80M |
| 3 | Bhatt Elizabeth | Pres, COO | — | $1.45M |
| 4 | Long Daniel D. | SVP, Drug Discovery | — | $951.3K |
| 5 | Third Rock Ventures V, L.P. | 10% | — | -$7.40M |
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-14 17:44 | 2026-08-12 | SEPN | Septerna, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $50.27 | +147.2K | 6.07M | +2% | +$7.40M |
| T | 2026-05-28 16:15 | 2026-05-26 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $40.05 | -18.6K | 6.28M | -0.3% | -$743.8K |
| T | 2026-05-13 19:06 | 2026-05-11 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $40.24 | -133.6K | 6.30M | -2% | -$5.38M |
| MT | 2026-05-11 17:07 | 2026-05-07+ | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $40.12 | -276.5K | 6.43M | -4% | -$11.09M |
| T | 2026-04-21 19:36 | 2026-04-17 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $40.32 | -426.0K | 6.71M | -6% | -$17.18M |
| D | 2024-06-10 | 2024-06-10 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | C - Cnv Deriv | $0.00 | +6.55M | 7.14M | +1,122% | $0 |
| DI | 2024-06-10 | 2024-06-10 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | C - Cnv Deriv | $0.00 | +969.2K | 969.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations